Comparative Pharmacology
Head-to-head clinical analysis: HEATHER versus NEXPLANON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEATHER versus NEXPLANON.
HEATHER vs NEXPLANON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Heather is a combination hormonal contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, inhibiting ovulation. Drospirenone, a spironolactone analog with anti-mineralocorticoid activity, also inhibits ovulation and may increase cervical mucus viscosity, impeding sperm penetration.
Progestin-only contraceptive that suppresses ovulation primarily by inhibiting the mid-cycle LH surge. It also thickens cervical mucus, impeding sperm penetration, and alters endometrial lining.
5 mg orally once daily, increased to 10 mg after 2 weeks if tolerated; maximum 20 mg daily.
68 mg subdermal implant inserted in the inner upper arm; provides contraception for up to 3 years.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours. Clinical context: Requires every-6-hour dosing for steady state; therapeutic drug monitoring recommended in renal impairment.
Terminal elimination half-life approximately 25 hours (range 20-30 hours) after removal; steady-state achieved within 3-4 days; clinical effect persists for 3-4 weeks post-removal due to residual subcutaneous depot.
Renal excretion of unchanged drug (60%) and hepatic metabolism with biliary/fecal elimination (40%).
Renal (40-50% as metabolites), fecal (30-40% as metabolites), with <1% unchanged in urine; enterohepatic circulation contributes to prolonged elimination.
Category C
Category C
Contraceptive
Contraceptive